Sumitomo Pharma America, Inc.
$48.1M 94,811 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported $47,893,935.05 across General Payments, Research, and Ownership to 137,083 physicians and teaching hospitals across 146,137 transactions.
- $47.9M Top 10% payer
- All-tracks total
- 146,137 Top 10% volume
- Transactions
- 137,083 Top 10% reach
- Recipients
- +$1.2M
- General Payments vs PY2023
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported $47,893,935.05 across all CMS Open Payments tracks (General + Research + Ownership) to 137,083 physicians and teaching hospitals in Program Year 2024 - ranking #50 of 1,925 reporting manufacturers (0.3% of the all-tracks industry total); General Payments alone were $10,789,046.70, averaging $349.38 per recipient.
How ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)'s $47.9M all-tracks total breaks down
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
98/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer iti-inc-d-b-a-intra-cellular-therapies-inc ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$47.9M · #50/1,925 · 0.3% industry · PY2024
- TOT $47.9M
- RANK #50
- SHARE 0.3%
- TXN 146,137
- RCP 137,083
- CAT 7
- GEN $10.8M
- ΔGEN +$1.2M
- TOP1 1.5%
- PY 2024
Volume peers
Nearest volume peer: Sumitomo Pharma America, Inc. ($48.1M)
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)'s CMS-reported General Payments increased by $1.2M (+12.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ITI, INC. (D/B/A INTRA-CELLULAR THERAPIES, INC.)PY2023: ITI, INC. (D/B/A INTRA-CELLULAR THERAPIES, INC.)PY2024: ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.). Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $9,605,384.04
- PY2024
- $10,789,046.70
What the Data Shows for ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.), that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
2,171 transactions worth $5.9M make "Compensation for Services Other Than Consulting" the top general-payment category in the 7-category breakdown below, 54.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)'s 7-category general-payment breakdown at $5.9M, 54.9% of the reported total.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (54.9%), Food and Beverage (28.3%), and Travel and Lodging (8.6%). The remaining 4 categories make up 8.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $5.9M | 2,171 | 54.9% |
| Food and Beverage | $3.1M | 129,577 | 28.3% |
| Travel and Lodging | $923.3K | 3,244 | 8.6% |
| Consulting Fee | $807.9K | 214 | 7.5% |
| Royalty or License | $44.0K | 4 | 0.4% |
| Education | $33.8K | 1,870 | 0.3% |
| Space Rental or Facility Fees | $6.8K | 3 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $685,304.53 (6.4%) of $10,789,046.70 in this company's General Payments records across 29,384 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
The five named recipients with the highest reported General Payments from this company
- 1
Andrew Cutler
$164,049.60 across 154 reported transactions
- 2
Henry Nasrallah
$142,165.88 across 115 reported transactions
- 3
Charles Nguyen
$133,582.76 across 142 reported transactions
- 4
John Fenley
$125,004.36 across 163 reported transactions
- 5
Niku Singh
$120,501.93 across 135 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ranks #50 of 1,925 by total payments (top 3% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,759 of 1,838 by HHI (bottom 4% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Coastal Medical Technologies Llc : $69.5K total payments, HHI 58
- EMD Serono, Inc. : $10.0M total payments, HHI 58
- Abbvie Inc. : $156.7M total payments, HHI 57
- Journey Medical Corporation : $64.6K total payments, HHI 55
- Eisai Inc. : $7.1M total payments, HHI 55
- Amgen Inc. : $44.9M total payments, HHI 55
- ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) (this company) : $10.8M total payments, HHI 52
- Mylan Specialty L.P. : $1.4M total payments, HHI 51
- Virtus Pharmaceuticals LLC : $19.8K total payments, HHI 50
- Madrigal Pharmaceuticals : $4.5M total payments, HHI 49
- Electronic Waveform Lab, Inc. : $32.0K total payments, HHI 47
- Avvisto Therapeutics, LLC : $8.9K total payments, HHI 47
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.).
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.).
Showing 6 of 1,924 companies with CMS-reported payment data.
Cleerly, Inc.
$47.5M 910 recipients
Compare payment profiles
Scientia Vascular
$46.9M 191 recipients
Compare payment profiles
Novo Nordisk AS
$49.2M 804 recipients
Compare payment profiles
Vektor Medical Inc.
$49.6M 56 recipients
Compare payment profiles
Imperative Care, Inc
$45.6M 5,115 recipients
Compare payment profiles
Put this to use
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ranks #50 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.). Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.